Showing results (1651-1660 of 2,449) with videos related to

Sort By:
Pageof 245
Clinical and Translational Science|July 17, 2024
Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypesXiaojie Wu, Nanye Chen, Peiwen Hsu, et al.
Clinical and Translational Science|July 29, 2024
Assessing the net financial benefits of employing digital endpoints in clinical trialsJoseph A DiMasi, Abigail Dirks, Zachary Smith, et al.
Clinical and Translational Science|July 2, 2024
Integration of individual preclinical and clinical anti-infective PKPD data to predict clinical study outcomesVincent Aranzana-Climent, Wisse van Os, Amir Nutman, et al.
Clinical and Translational Science|July 1, 2024
Age-related off-label drug prescribing in pediatric patients in South Korea and consistency of labeling compared to the United States, Europe, and JapanBojung Park, Hyesung Lee, Hyeyoung Choi, et al.
Clinical and Translational Science|July 11, 2024
Dalzanemdor (SAGE-718), a novel, investigational N-methyl-D-aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose-finding studies in healthy participants and an open-label study in participants with Huntington's diseaseAaron Koenig, Michael Lewis, Jeff Wald, et al.
Clinical and Translational Science|July 8, 2024
A phase I thorough QT/QTc study evaluating therapeutic and supratherapeutic doses of avacopan in healthy participantsShichang Miao, Peter Staehr, Ezra Tai, et al.
Clinical and Translational Science|July 10, 2024
Protective effect of clusterin against interleukin-1β-induced apoptosis and inflammation in human knee osteoarthritis chondrocytesTachatra Ungsudechachai, Jiraphun Jittikoon, Sittisak Honsawek, et al.
Clinical and Translational Science|June 29, 2024
Using electronic health records for clinical pharmacology research: Challenges and considerationsEissa Jafari, Marisa H Blackman, Jason H Karnes, et al.
Clinical and Translational Science|July 1, 2024
A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participantsAna Liza Andresan Sun, John David Gillies, Yang Shen, et al.
Clinical and Translational Science|August 17, 2024
Dose-dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampinNicolas Hohmann, Anna S Friedrichs, Jürgen Burhenne, et al.
Pageof 245